ClinicalTrials.gg
TerminatedNCT01056809PGCUpdated May 31, 2012

Treatment Strategies for Primarily Generalized Colorectal Cancer

An interventional study of Chemotherapy and surgery in Colorectal Cancer, sponsored by Vrinnevi Hospital. Terminated at 10 sites in Sweden. Per ClinicalTrials.gov, last updated 2012-05-31.

Sponsored by Vrinnevi Hospital · Not applicable, Interventional, and Treatment

How we know

Why this study was terminated
Too slow recruitment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 124 studies in Colorectal Neoplasms with a site in Sweden — 27 open to participants now, 38 under way, 10 of them phase 3. Colorectal Neoplasms · Sweden.

Enrollment
87th of 89
15 · median 215
Started
2010
with 4 others
No phase
25 of 124
10 open now
Registered
25th of 124
by date

Among the 124 studies in Colorectal Neoplasms with a site in Sweden, this one is the 87th largest by enrollment of the 89 interventional ones that give a count, is one of 5 that started in 2010, is one of 25 with no phase, and was the 25th registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

27 of the 124 studies in Colorectal Neoplasms with a site in Sweden are open now. Recruiting first, the newest first:

22 more — sign in →

All 27 open studies →

A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 124 studies in Colorectal Neoplasms with a site in Sweden, or all of them as a file.
02

Study summary

For patients with primarily generalized colorectal cancer two treatment strategies are compared to establish which strategy gives best overall survival.

The traditional strategy is to first resect the primary colorectal tumour and then treat the metastases with chemotherapy followed if possible by surgery.

The alternative strategy is to first treat the metastases with chemotherapy followed if possible by surgery and only resect the primary colorectal tumour if there is hope for cure or if symptoms develop that necessitates treatment.

Read the detailed description

Patients are randomized between the two treatment strategies mentioned above. After initial treatment the patients are categorized as palliative or treated with curative intent. Patients are followed with quality of life evaluations every 6 months. Outpatient visits, hospital care, examinations and treatment are recorded as well as complications and side effects. Survival is recorded and for those patients treated with curative intent the tumour situation 3 years after randomization is evaluated.

03

Conditions studied

  • Colorectal Cancer

Keywords

  • Colorectal cancer
  • Metastases
  • Treatment strategies
  • Colorectal cancer with synchronous metastases
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with primarily generalized colorectal cancer diagnosed by pathology or typical appearance on x-ray or at endoscopy and where there is uncertainty regarding best treatment strategy

Exclusion criteria

Exclusion Criteria:

  • Patients not willing to participate or unable to sign .
  • Patients with other with potential
  • Patients where synchronous resection of primary tumour and metastases is planned
  • Patients not fit for chemotherapy or surgery
  • Patients with locally unresectable primary tumours
  • Patients with symptoms from primary colorectal tumour necessitating resection
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Active comparator
    Traditional strategy

    First resection of the primary colorectal tumour, then treatment of metastases with chemotherapy and if possible surgery.

    Procedure: Chemotherapy and surgery

  • Active comparator
    Alternative strategy

    First treatment of metastases with chemotherapy and if possible surgery, later resection of primary colorectal tumour if hope for cure or if symptoms develope that necessitates treatment

    Procedure: Chemotherapy and surgery

Interventions

  • ProcedureChemotherapy and surgery

    Treatment not specified but in accordance with national guidelines

06

What researchers measure

Primary outcomes

  1. Overall survival

    Time frame: 3 years after completion of study

Secondary outcomes

  1. 3 year survival for patients treated with curative intent

    Time frame: 3 years after randomization

  2. Palliative patients not receiving chemotherapy treated with the traditional strategy

    Time frame: Completion of study

  3. Quality of life

    Time frame: Every 6 months up to 3 years

  4. Health care consumption

    Time frame: Completion of study

  5. Complications and side effects

    Time frame: Completion of study

07

Study locations

10 sites
  • Höglandssjukhuset
    Eksjö, SE 57581, Sweden
  • Department of Surgery
    Gävle - Hudiksvall, Sweden
  • Länssjukhuset Ryhov
    Jönköping, SE 55185, Sweden
  • Länssjukhuset
    Kalmar, SE 39185, Sweden
  • Universitetssjukhuset
    Linköping, SE 58185, Sweden
  • Vrinnevisjukhuset
    Norrköping, SE 601 82, Sweden
  • Karolinska Universitetssjukhuset
    Stockholm, SE 17176, Sweden
  • Akademiska sjukhuset
    Uppsala, SE 75185, Sweden
  • Värnamo sjukhus
    Värnamo, SE 33185, Sweden
  • Centrallasarettet
    Västerås, SE 72189, Sweden
08

References and documents

Publications

  • Mentha G, Majno PE, Andres A, Rubbia-Brandt L, Morel P, Roth AD. Neoadjuvant chemotherapy and resection of advanced synchronous liver metastases before treatment of the colorectal primary. Br J Surg. 2006 Jul;93(7):872-8. doi: 10.1002/bjs.5346. PubMed 16671066 ↗
  • Scoggins CR, Meszoely IM, Blanke CD, Beauchamp RD, Leach SD. Nonoperative management of primary colorectal cancer in patients with stage IV disease. Ann Surg Oncol. 1999 Oct-Nov;6(7):651-7. doi: 10.1007/s10434-999-0651-x. PubMed 10560850 ↗
  • Benoist S, Pautrat K, Mitry E, Rougier P, Penna C, Nordlinger B. Treatment strategy for patients with colorectal cancer and synchronous irresectable liver metastases. Br J Surg. 2005 Sep;92(9):1155-60. doi: 10.1002/bjs.5060. PubMed 16035135 ↗
  • Scheer MG, Sloots CE, van der Wilt GJ, Ruers TJ. Management of patients with asymptomatic colorectal cancer and synchronous irresectable metastases. Ann Oncol. 2008 Nov;19(11):1829-35. doi: 10.1093/annonc/mdn398. Epub 2008 Jul 28. PubMed 18662955 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2010, a primary completion of May 2012 and a completion of May 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2010
First posted
Jan 26, 2010
Start
Jan 2010
Primary completionActual
May 2012
CompletionActual
May 2012
Last update
May 31, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 31, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01056809
Lead sponsor
Vrinnevi Hospital
Collaborators
Medical Research Council of Southeast Sweden
Responsible party
Gunnar Arbman (Consultant surgeon, Vrinnevi Hospital) — Principal investigator
First posted
Jan 26, 2010
Start date
Jan 2010
Primary completion
May 2012
Completion
May 2012
Last update
May 31, 2012

Study contacts

Gunnar Arbman, MD, PhD
principal investigator · Department of Surgery in Östergötland
Per Sandström, MD, PhD
study chair · Department of Surgery in Östergötland
Hans Starkhammar, MD, PhD
study chair · Regional Oncologic Center, Linköping
Bengt Glimelius, Professor
study chair · University of Uppsala, The Karolinska University Hospital, Stockholm
Lars Lundell, Professor
study chair · The Karolinska University Hospital, Stockholm
Per-Olof Nyström, Professor
study chair · The Karolinska Universtiy Hospital, Stockholm
Ulf Gunnarsson, Professor
study chair · The Karolinska University hospital, Stockholm
Lars Påhlman, Professor
study chair · Uppsala University

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion